With multiple ADCs now available for use in gynecologic cancers, treatment decision-making incorporates biomarker nuances and raises sequencing questions.
|Videos|October 13, 2015
Dr. Memarzadeh on Recurrence Rates in Ovarian Cancer
Author(s)Sanaz Memarzadeh, MD, PhD
Sanaz Memarzadeh, MD, PhD, gynecologic oncology, obstetrics and gynecology, University of California, Los Angeles, discusses recurrence rates in ovarian cancer.
Advertisement
Sanaz Memarzadeh, MD, PhD, gynecologic oncology, obstetrics and gynecology, University of California, Los Angeles, discusses recurrence rates in ovarian cancer.
The challenge with epithelial ovarian cancer, Memarzadeh says, is that the majority of patients present with advanced disease due to lack of identified biomarkers and little to no symptoms.
Therefore, in patients with stage III to IV epithelial ovarian cancer, approximately 80% to 85% relapse, despite undergoing surgeries and/or chemotherapy.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on OncLive
1
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
2
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
3
Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape
4
Dr Warren on the Goal of the 4WARD Trial Evaluating Mavorixafor in Chronic Neutropenia
5